Developing the Gold Standard Non-Invasive Diagnostic for Endometriosis
A Women's Health Diagnostics Biotechnology Company Building the Next Generation of Accessible Molecular Testing
A molecular signal specific to the disease , not a proxy for inflammation
The Endometriosis Diagnostic Challenge
Endometriosis takes an average of 7 to 10 years to diagnose. For many women, significantly longer.
Veridyn Diagnostics is building a women's health biotechnology company dedicated to advancing non-invasive molecular diagnostics grounded in biological precision and translational discipline.
Our objective is to establish a new standard for earlier, non-invasive detection of endometriosis. Once that foundation is established and validated, the same framework expands to additional women's health conditions where diagnostic clarity is equally limited, with the long-term goal of connecting molecular findings directly to treatment decisions.
Decorative word cloud featuring terms related to women's health diagnostics including endometriosis, pelvic pain, adenomyosis, fibroids, biomarkers, infertility, and laparoscopy.
The Diagnostic Gap
US Economic Burden
Annual cost in lost productivity, healthcare, and surgery. One of the most expensive unaddressed conditions in women's health.
Only Confirmed by Laparoscopy
An invasive procedure that is expensive, carries risk, and can still miss lesions.
FDA-Cleared Non-Invasive Tests
No non-invasive diagnostic for endometriosis exists today.
A note on equity: Diagnostic delay is not equal across populations. Women of color are diagnosed later, dismissed more often, and underrepresented in the research shaping clinical guidelines. Veridyn's validation is intentionally designed to reflect the full diversity of the population this test is meant to serve.
1 in 2 women experiencing infertility has endometriosis. Most do not know it.
Endometriosis is one of the leading causes of infertility, yet it is rarely the first thing investigated. Earlier diagnosis changes what is possible.
A New Standard
Begins Here
Endometriosis represents one of the largest unmet needs in women's health diagnostics. It affects millions, is frequently diagnosed only after years of uncertainty, and still depends on surgical confirmation.
Imaging can help when disease is extensive and interpreted by a specialist. But neither ultrasound nor MRI can definitively confirm the diagnosis, and superficial endometriosis is frequently missed entirely.
In the meantime, women are managed on pain medications, hormonal therapies, and surgery. Even the best surgical option, excision, does not guarantee lasting relief. Ablation, one of the most commonly performed procedures, removes surface tissue but frequently leaves disease behind.
Earlier, non-invasive detection would change the trajectory for millions of women.
A Growing Women's Health
Diagnostic Pipeline
Endometriosis is the starting point. As each indication is validated, the same framework extends to the next, each building on the same standard of evidence.
Endometriosis
Pilot and verification phases underway. Blood-based RNA classifier in development.
Additional Women's Health Conditions
The architecture is designed to extend to conditions where diagnostic clarity is equally limited.
A Scalable Diagnostic Framework
One blood draw. Multiple answers. Integrated into routine gynecologic care.
Stay Connected
Follow the science as it moves forward
Research updates, funding developments, and ways to get involved. No noise, only what matters.
We respect your privacy.